Paediatric nonalcoholic fatty liver disease

Current Opinion in Gastroenterology

Volumn 29, Issue 3, 2013, Pages 279-284

  Alisi, Anna ^a   Carpino, Guido ^b   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

diagnosis; fibrosis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; DOCOSAHEXAENOIC ACID; INSULIN SENSITIZING AGENT; METFORMIN; URSODEOXYCHOLIC ACID;

DIET THERAPY; DISEASE COURSE; GENOTYPE; HEALTH PROGRAM; HEREDITY; HISTOPATHOLOGY; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NUTRITION; PATHOGENESIS; REVIEW; SCORING SYSTEM;

CHILD; DIET; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIFE STYLE; RISK FACTORS;

EID: 84876291077     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835ff95e     Document Type: Review

References (49)

1. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7:195-203.
2. Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009; 155:469-474.
3. Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2012. [Epub ahead of print]
4. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118:1388-1393.
5. Pacifico L, Poggiogalle E, Cantisani V, et al. Pediatric nonalcoholic fatty liver disease: a clinical and laboratory challenge. World J Hepatol 2010; 2:275-288.
6. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58:1538-1544.
7. Nobili V, Bedogni G, Berni Canani R, et al. The potential role of fatty liver in paediatric metabolic syndrome: a distinct phenotype with high metabolic risk? Pediatr Obes 2012; 7:e75-e80.
8. Alisi A, Feldstein AE, Villani A, et al. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012; 9:152-161.
9. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16:5286-5296.
10. Alisi A, Bedogni G, De Vito R, et al. Relationship between portal chronic inflammation and disease severity in paediatric nonalcoholic fatty liver disease. Dig Liver Dis 2011; 43:143-146.
11. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42:641-649.
12. Patton HM, Lavine JE, Van Natta ML, et al. Clinical correlates of histopatho-logy in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1961-1971.
13. Valenti L, Alisi A, Galmozzi E, et al. I148 M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52:1274-1280.
14. Valenti L, Motta BM, Alisi A, et al. LPIN1 rs13412852 polymorphism in pediatric non-alcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2012; 54:588-593.
15. Rossi F, Bellini G, Alisi A, et al. Cannabinoid receptor type 2 functional variant influences liver damage in children with nonalcoholic fatty liver disease. PloS One 2012; 7:e42259.
16. Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-g coactivator-1a gene is associated with non alcoholic fatty liver disease in obese children. Am J Clin Nutr 2013; 97:326-331.
17. Adams LA, White SW, Marsh JA, et al. Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology 2013; 57:590-600.
18. Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012; 55:781-789.
19. Al-Serri A, Anstee QM, Valenti L, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. J Hepatol 2012; 56:448-454.
20. Fowden AL, Giussani DA, Forhead AJ. Intrauterine programming of physiological systems: causes and consequences. Physiology (Bethesda) 2006; 21:29-37.
21. Nobili V, Marcellini M, Marchesini G, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care 2007; 30:2638-2640.
22. Alisi A, Panera N, Agostoni C, Nobili V. Intrauterine growth retardation and nonalcoholic fatty liver disease in children. Int J Endocrinol 2011; 2011: 269853.
23. Nobili V, Bedogni G, Alisi A, et al. A protective effect of breastfeeding on the progression of nonalcoholic fatty liver disease. Arch Dis Child 2009; 94:801-805.
24. Alisi A, Cianfarani S, Manco M, et al. Nonalcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 2012; 44:29-40.
25. Mager DR, Patterson C, So S, et al. Dietary and physical activity patterns in children with fatty liver. Eur J Clin Nutr 2010; 64:628-635.
26. Papandreou D, Karabouta Z, Rousso I. Are dietary cholesterol intake and serum cholesterol levels related to nonalcoholic fatty liver disease in obese children? Cholesterol 2012; 2012:572820.
27. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of nonobese patients with nonalcoholic fatty liver disease: the significance of dietary cholesterol. Scan J Gastroenterol 2009; 44:471-477.
28. Jin R, Le NA, Liu S, et al. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab 2012; 97:E1088-E1098.
29. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23: 203-208.
30. Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010; 13:397-402.
31. Frasinariu OE, Ceccarelli S, Alisi A, et al. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2012. [Epub ahead of print]
32. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010; 50:645-649.
33. De Vito R, Alisi A, Masotti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med 2012; 30:49-56.
34. Torres DM, Harrison SA. Hepatic progenitor cells: another piece in the nonalcoholic fatty liver disease puzzle. Hepatology 2012; 56:2013-2015.
35. Nobili V, Carpino G, Alisi A, et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012; 56:2142-2153.
36. Swiderska-Syn M, Suzuki A, Guy CD, et al. Hedgehog pathway and pediatric nonalcoholic fatty liver disease. Hepatology 2013. [Epub ahead of print]
37. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012; 54:700-713.
38. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am JGastroenterol 2012; 107:811-826.
39. Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with nonalcoholic fatty liver disease. BMC Med 2009; 7:21.
40. Alkhouri N, De Vito R, Alisi A, et al. Development and validation of a new histological score for pediatric nonalcoholic fatty liver disease. J Hepatol 2012; 57:1312-1318.
41. Alisi A, Nobili V. Nonalcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition 2012; 28:722-726.
42. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for nondiabetic paediatric nonalcoholic steatohe-patitis. Aliment Pharmacol Ther 2005; 21:871-879.
43. Nobili V, Manco M, Ciampalini P, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008; 30:1168-1176.
44. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48:119-128.
45. Lavine JE, Schwimmer JB, Van Natta ML. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC Randomized Controlled Trial. JAMA 2011; 305:1659-1668.
46. Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136:739-743.
47. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with nonalcoholic fatty liver disease: double-blind randomized controlled clinical trial. Arch Dis Child 2011; 96:350-353.
48. Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2012. [Epub ahead of print]
49. Alisi A, Nobili V. Nonalcoholic fatty liver disease: targeted therapy in children-what is the right way? Nat Rev Gastroenterol Hepatol 2011; 8:425-426.